{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"4.250","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"416,437,544","primaryexch":"香港交易所","ric":"2126.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BN4NLR9","am":"6.81","iv":"","ew_strike":"","as":"4.140","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"4.100","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"1.230","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"劉敏","underlying_ric":"2126.HK","hi52":"6.440","issuer_name":"藥明巨諾（開曼）有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"4.010","mkt_cap":"1.70","f_aum_hkd":null,"ew_sub_per_to":"","ls":"4.100","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.040","aum":"","issued_shares_class_B":null,"vo":"1.66","secondary_listing_flag":false,"listing_date":"2020年11月3日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"藥明巨諾（開曼）有限公司 - B","nm_s":"藥明巨諾－Ｂ","sym":"2126","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"藥明巨諾（開曼）有限公司是一家主要從事細胞免疫治療產品的研究及開發、生產及上市的公司。該公司建立了一個細胞免疫治療產品開發的一體化平台以及一條涵蓋血液惡性腫瘤、實體瘤及自身免疫性疾病的產品管線。該公司的主要產品倍諾達是該公司在Juno（一家百時美施貴寶的公司）的嵌合抗原受體T細胞（CAR-T）細胞工藝平台的基礎上，自主開發的一款靶向CD19的自體CAR-T細胞免疫治療產品。該公司主要在國內市場開展業務。","op":"4.250","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>勿地臣街1號<br/>時代廣場<br/>2座31樓","pc":"-0.97","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"4.140","isin":"KYG5210T1040","moneyness":""}},"qid":"1759074420244"}
